Fortress Biotech, Inc. (FBIO)

Price$2.65

Value ScoreB

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-13.95%

Price vs S&P 500 (4W)10.89%

VGM Score64.80

Market Capitalization$88.03M

P/E Ratio (Annual)12.92x

All Metrics

Book Value / Share (Quarterly)$4.89

P/TBV (Annual)5.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-5.82%

Cash Flow / Share (Quarterly)$4.75

Price vs S&P 500 (YTD)-35.75%

Gross Margin (TTM)66.22%

Net Profit Margin (TTM)193.12%

EPS (TTM)$3.44

10-Day Avg Trading Volume0.41M

EPS Excl Extra (TTM)$3.44

Revenue Growth (5Y)6.77%

EPS (Annual)$0.24

Dividend / Share (Annual)$0.02

ROI (Annual)6.23%

Gross Margin (Annual)66.92%

Net Profit Margin (5Y Avg)-69.82%

Cash / Share (Quarterly)$7.71

P/E Basic Excl Extra (TTM)0.69x

Revenue Growth QoQ (YoY)22.06%

P/E Normalized (Annual)12.92x

ROA (Last FY)3.67%

Revenue Growth TTM (YoY)14.50%

EBITD / Share (TTM)$-0.74

ROE (5Y Avg)-144.95%

Operating Margin (TTM)-43.36%

Cash Flow / Share (Annual)$-2.10

P/B Ratio0.54x

P/B Ratio (Quarterly)0.55x

Net Income / Employee (Annual)$87,400

EV / Revenue (TTM)-1.94x

Net Interest Coverage (TTM)-3.18x

ROA (TTM)57.83%

EV / EBITDA (TTM)-0.82x

EPS Incl Extra (Annual)$0.24

Current Ratio (Annual)2.49x

Quick Ratio (Quarterly)2.72x

3-Month Avg Trading Volume0.63M

52-Week Price Return40.96%

P/E Incl Extra (TTM)0.69x

Revenue / Employee (TTM)$848,200

Tangible BV / Share (Quarterly)$4.09

P/S Ratio (Annual)1.39x

Asset Turnover (Annual)0.34x

52-Week High$4.53

Operating Margin (5Y Avg)-194.96%

EPS Excl Extra (Annual)$0.24

CapEx CAGR (5Y)25.86%

Tangible BV CAGR (5Y)3.44%

26-Week Price Return-6.03%

Quick Ratio (Annual)2.20x

13-Week Price Return-15.34%

Total Debt / Equity (Annual)1.19x

Current Ratio (Quarterly)2.86x

Enterprise Value$-128.43M

Revenue / Share Growth (5Y)-24.91%

Asset Turnover (TTM)0.30x

Book Value / Share Growth (5Y)-36.92%

Revenue / Employee (Annual)$811,100

Inventory Turnover (Annual)1.74x

Pretax Margin (Annual)-53.01%

Cash / Share (Annual)$2.53

3-Month Return Std Dev57.69%

Gross Margin (5Y Avg)62.38%

Net Income / Employee (TTM)$1,638,100

ROE (Last FY)13.66%

Net Interest Coverage (Annual)9.58x

EPS Basic Excl Extra (Annual)$0.24

Receivables Turnover (TTM)3.08x

EV / Free Cash Flow (TTM)-0.81x

Total Debt / Equity (Quarterly)0.24x

EPS Incl Extra (TTM)$3.44

Receivables Turnover (Annual)3.16x

ROI (TTM)98.68%

Dividend Growth Rate (5Y)-54.94%

P/S Ratio (TTM)1.33x

Pretax Margin (5Y Avg)-192.91%

Revenue / Share (Annual)$2.27

Tangible BV / Share (Annual)$0.71

Forward P/E2.49x

Price vs S&P 500 (52W)16.59%

P/E Ratio (TTM)0.69x

Year-to-Date Return-27.60%

5-Day Price Return3.11%

EPS Normalized (Annual)$0.24

ROA (5Y Avg)-22.03%

Net Profit Margin (Annual)10.77%

Month-to-Date Return-5.36%

Cash Flow / Share (TTM)$-25.80

EBITD / Share (Annual)$-1.39

Operating Margin (Annual)-68.12%

LT Debt / Equity (Annual)1.19x

P/CF (TTM)0.56x

ROI (5Y Avg)-44.39%

P/E Excl Extra (TTM)0.69x

LT Debt / Equity (Quarterly)0.23x

EPS Basic Excl Extra (TTM)$3.44

P/TBV (Quarterly)0.66x

Payout Ratio (Annual)9.74%

P/B Ratio (Annual)2.28x

Dividend / Share (TTM)$0.02

Inventory Turnover (TTM)2.05x

Pretax Margin (TTM)201.45%

Book Value / Share (Annual)$1.59

Price vs S&P 500 (13W)-23.59%

Dividend Yield (TTM)0.57%

Beta1.22x

Revenue / Share (TTM)$1.72

ROE (TTM)163.88%

52-Week Low$1.70

vGradeB

gGradeB

mGradeC

vgmGradeB

Show chart for

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.13

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
FBIOFortress Biotech, Inc.	B	B	C	$2.65
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Fortress Biotech is a biopharmaceutical company focused on acquiring, developing, and commercializing dermatology and therapeutic products. Its portfolio includes key dermatology brands—Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm—which represent the majority of revenues. The company also operates in oncology and other therapeutic sectors through its subsidiaries.